Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 2, 2006, Pages 521-523

  Howell, A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB;

BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; ENDOMETRIUM CANCER; GENETIC TRANSCRIPTION; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

ANIMALS; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33748803877     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00686.x     Document Type: Conference Paper

References (17)

1. Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens?. J Steroid Biochem Mol Biol 2005;93:237-247.
2. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-3873.
3. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990;87:6883-6887.
4. McClelland RA, Manning DL, Gee JM, et al. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat 1996;41:31-41.
5. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000;7:17-28.
6. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-6746.
7. Robertson JF. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 2004;30:695-706.
8. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-238.
9. Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104:236-239.
10. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-935.
11. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-870s.
12. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002;87:1354-1359.
13. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-750.
14. Abram P, Maas N, Rea D, Simon SD, Steger GG. Case studies of fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005;31(Suppl 2):S17-S25.
15. Pietras RJ, Marquez DC, Chen HW, Ayala R, Ramos LB, Slamon DJ. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat 2003;82(Suppl 1):S12, 22 (abstract).
16. Gee JMW, Harper ME, Hutcheson IR, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003;144:5105-5117.
17. Howell A. Fulvestrant ('Faslodex'): Current and future role in breast cancer management. Crit Rev Oncol Hematol 2005;57:265-273.